HCPCS | Generic Name | Brand Name | Strength | SEER*Rx Category | Major Drug Class | Minor Drug Class | Oral (Y/N) | FDA Approval Year | FDA Discontinuation Year | CMS Effective Date | CMS Discontinuation Date | Status |
---|---|---|---|---|---|---|---|---|---|---|---|---|
NA | Mitotane | Lysodren | unspecified | Chemotherapy | Miscellaneous Agent | Adrenal Suppressant | Yes | 1970 | In Use | |||
NA | Aprepitant | Emend | 80 mg | Ancillary Therapy | Antiemetic | Substance P/Neurokinin 1 | Yes | 2003 | In Use | |||
NA | Finasteride | Proscar | 5mg | Ancillary Therapy | Protective Agent | 5-alpha Reductase Inhibitor | Yes | 1992 | In Use | |||
NA | Sorafenib | Nexavar | 200 mg | Chemotherapy | Tyrosine Kinase Inhibitor | VEGFR, FGF, PDGFR,KIT,RET, CRAF, BRAF | Yes | 2005 | In Use | |||
NA | Sotorasib | Lumakras | Multiple | Chemotherapy | RAS Inhibitor | KRASG12C | Yes | 2021 | In Use | |||
S0088 | Imatinib mesylate | Gleevec | 100 mg | Chemotherapy | Tyrosine Kinase Inhibitor | BCR-ABL | Yes | 2001 | Jan 1, 2002 | In Use | ||
Inovolisib | Itovebi | 3mg, 9mg | Chemotherapy | Enzyme Inhibitor | PI3K⍺ | Yes | 2024 | In Use | ||||
NA | Nilutamide | Anadron, Nilandron | 150 mg | Hormonal Therapy | Androgen Receptor Inhibitor | Yes | 1996 | In Use | ||||
NA | Thalidomide | Thalomid | 100 mg | Immunotherapy | Immunomodulator | Thalidomide Analog | Yes | 1998 | In Use | |||
NA | Ketoconazole | Apo-Ketoconazole | 200 mg | Hormonal Therapy | Androgen Receptor Inhibitor | Imidazole Derivative | Yes | 1981 | In Use | |||
NA | Dasatinib | Sprycel | 80 mg | Chemotherapy | Tyrosine Kinase Inhibitor | BCR-ABL | Yes | 2006 | In Use | |||
NA | Naldemedine | Symproic | 0.2mg | Ancillary Therapy | Opioid Antagonist | Yes | 2018 | In Use | ||||
NA | Sunitinib malate | Sutent | 12.5 mg | Chemotherapy | Tyrosine Kinase Inhibitor | VEGFR, FLT, PDGFR,KIT, RET, CSF | Yes | 2006 | In Use | |||
S0187 | Tamoxifen Citrate | Nolvadex, Nolvadex-D, Soltamox | 10 mg | Hormonal Therapy | Selective Estrogen Receptor Modulator (SERM) | Yes | 1977 | Jan 1, 2002 | In Use | |||
NA | Midostaurin | Rydapt | 25 mg | Chemotherapy | Tyrosine Kinase Inhibitor | FLT3 | Yes | 2017 | In Use | |||
NA | Palbociclib | Ibrance | 100 mg | Chemotherapy | Cyclin Dependent Kinase Inhibitor | CDK 4/6 | Yes | 2015 | In Use | |||
NA | lenvatinib | Lenvima | 4 mg | Chemotherapy | Tyrosine Kinase Inhibitor | VEGFR, FGF, PDGFR,KIT,RET | Yes | 2015 | In Use | |||
NA | venetoclax | Venclexta | 100 mg | Chemotherapy | Enzyme Inhibitor | BCL-2 | Yes | 2016 | In Use | |||
NA | Selpercatinib | Retevmo | 40mg, 80mg | Chemotherapy | Tyrosine Kinase Inhibitor | VEGFR | Yes | 2020 | In Use | |||
NA | idelalisib | Zydelig | 100 mg | Chemotherapy | Enzyme Inhibitor | PI3K | Yes | 2014 | In Use | |||
NA | Trifluridine and Tipiracil | Lonsurf | 15/6.14 mg | Chemotherapy | Antimetabolite | Pyrimidine Analog | Yes | 2015 | In Use | |||
J7506 | Prednisone | Deltasone, PredniSONE Intensol, Rayos | 5 mg | Hormonal Therapy | Adrenal Glucocorticoid | Corticosteroid | Yes | 1974 | Jan 1, 1989 | Dec 31, 2015 | No Longer Used | |
S0181 | Ondansetron | Zofran, Zofran ODT, Zuplenz | 4 mg | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Yes | 1991 | Jan 1, 2002 | Dec 31, 2011 | No Longer Used | |
NA | Testolactone | Teslac | 250 mg | Hormonal Therapy | Androgen | Yes | 1970 | Jun 25, 2005 | No Longer Used | |||
NA | Pemigatinib | Pemazyre | 4.5mg, 9mg, 13.5mg | Chemotherapy | Tyrosine Kinase Inhibitor | FGFR1, FGFR2, FGFR3 | Yes | 2020 | In Use |
The use of NA indicates that the HCPCS code was Not Available. NA may mean that a) the HCPCS code has
not yet been created (new drug), b) the drug is given as an oral drug or alternative route (only in
specific instances are HCPCS assigned to these medications), or c) the HCPCS could not be found or is
truly not available.